Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
For people previously infected with COVID-19, analysis and assessment showed an 88% lower rate of hospitalization or death for at least 10 months compared to people who had no pre-existing disease .
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
Survivors of childhood brain cancer are more likely to be held back in school
2.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
3.
'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma
4.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
5.
Hypnotherapy may offer real benefits for cancer patient care
1.
The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment
2.
Thyroidectomy & Survival: Highlights from ASCO 2025 and Current U.S. Findings
3.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
4.
Understanding Mantle Cell Lymphoma Prognosis.
5.
Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge